ClinicalTrials.gg
CompletedNCT00848536Updated Apr 6, 2012Results posted

Efficacy Study of Travoprost APS Versus TRAVATAN

A Phase 3 interventional study of Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution and Travoprost 0.004% (BAK-preserved) Eye Drops, Solution in Open Angle Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-06.

Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
371
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Enrollment
8th of 45
371 · median 135
Started
2009
the only one that year
Phase 3
16 of 46
none open now
Registered
22nd of 46
by date
Lead sponsor
29 of 46
Alcon Research

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 8th largest by enrollment of the 45 interventional ones that give a count, is the only one that started in 2009, is one of 16 in phase 3, and was the 22nd registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

A Multi-Center Double-masked Study of the Safety and Efficacy of Travoprost APS Compared to TRAVATAN in Patients with Open-angle Glaucoma or Ocular Hypertension

03

Conditions studied

  • Open Angle Glaucoma
  • Ocular Hypertension

Keywords

  • OAG
  • OHT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older, either gender and any race.
  • Open Angle Glaucoma (OAG) or Ocular Hypertension (OHT).
  • Not currently on any IOP-lowering medication or currently on a stable treatment (i.e, at least 30 days) with and IOP-lowering monotherapy.
  • All patients: Mean IOP in same eye (at both Eligibility 1 \& 2 Visits):

    ≥ 24 and ≤ 36 mmHg at 9 AM; and ≥ 21 and ≤ 36 mmHg at 11 AM \& 4 PM.

  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Females of not meeting conditions set in the protocol.
  • Severe central visual field loss.
  • Angle Shaffer grade \< 2.
  • Cup/disc ratio > 0.8 (horizontal or vertical measurement).
  • Best corrected visual acuity (VA) score worse than 55 ETDRS letters read (equivalent to approximately 20/80 Snellen or 0.25 decimal).
  • Intraocular surgery or trauma within last 6 months.
  • Any abnormality preventing reliable applanation tonometry.
  • History of or current ocular pathology (including severe dry eye) that would affect the conduct of the study.
  • Allergy/ to study medications.
  • Unable to discontinue use of all IOP-lowering medications for a minimum of 5 to 28 days prior to the Eligibility Visit.
  • Less than 30 days stable dosing regimen of medications used on a chronic basis that may affect IOP.
  • Use of any additional topical or systemic ocular hypotensive medication during the study.
  • Therapy with another agent within 30 days prior to the Screening visit.
  • Other protocol-defined exclusion criteria may apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
371 participants (actual)

Study arms

  • Experimental
    TRAVATAN APS

    One drop once daily in the evening for 3 months

    Drug: Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution

  • Active comparator
    TRAVATAN

    One drop once daily in the evening for 3 months

    Drug: Travoprost 0.004% (BAK-preserved) Eye Drops, Solution

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Intraocular Pressure at 9:00 am

    For an individual patient, two consecutive IOP measurements for each eye were taken. The mean IOP values for each individual patient's eye were rounded up to the next whole number if the value was ≥ 0.5 mmHg All IOP measurements were performed with a Goldmann applanation tonometer. All IOP measurements for any individual subject were to be performed preferably by the same operator using the same tonometer. Mean IOP for the patient's worse eye at baseline was used in the primary endpoint analysis. If both eyes were equal, then the right eye was selected for analysis

    Time frame: 3 months (measured at 9:00 am)

  2. Mean Intraocular Pressure at 11:00 am

    For an individual patient, two consecutive IOP measurements for each eye were taken. The mean IOP values for each individual patient's eye were rounded up to the next whole number if the value was ≥ 0.5 mmHg All IOP measurements were performed with a Goldmann applanation tonometer. All IOP measurements for any individual subject were to be performed preferably by the same operator using the same tonometer. Mean IOP for the patient's worse eye at baseline was used in the primary endpoint analysis. If both eyes were equal, then the right eye was selected for analysis

    Time frame: 3 months (measured at 11:00 am)

  3. Mean Intraocular Pressure at 4:00 pm

    For an individual patient, two consecutive IOP measurements for each eye were taken. The mean IOP values for each individual patient's eye were rounded up to the next whole number if the value was ≥ 0.5 mmHg All IOP measurements were performed with a Goldmann applanation tonometer. All IOP measurements for any individual subject were to be performed preferably by the same operator using the same tonometer. Mean IOP for the patient's worse eye at baseline was used in the primary endpoint analysis. If both eyes were equal, then the right eye was selected for analysis

    Time frame: 3 months (measured at 4:00 pm)

07

Results

Posted Mar 8, 2011

Participant flow

Patients were recruited from 30 study centers: 8 in the US, 6 in Mexico, 2 in Brazil, 4 in India, 2 in Australia, 2 in New Zealand, 2 in Latvia, and a single site in each: Taiwan, France, Belgium, and Italy.

Participant flow — Overall Study
MilestoneTRAVATAN APSTRAVATAN
Started185186
Completed181179
Not completed47
Withdrew: Adverse event22
Withdrew: Withdrawal by subject01
Withdrew: Protocol violation01
Withdrew: Noncompliance10
Withdrew: Inadequate control of iop11
Withdrew: Patient moved02

Outcome measures

PrimaryMean Intraocular Pressure at 9:00 am

For an individual patient, two consecutive IOP measurements for each eye were taken. The mean IOP values for each individual patient's eye were rounded up to the next whole number if the value was ≥ 0.5 mmHg All IOP measurements were performed with a Goldmann applanation tonometer. All IOP measurements for any individual subject were to be performed preferably by the same operator using the same tonometer. Mean IOP for the patient's worse eye at baseline was used in the primary endpoint analysis. If both eyes were equal, then the right eye was selected for analysis

Time frame:
3 months (measured at 9:00 am)
Reported as:
Least squares mean · mmHg
Mean Intraocular Pressure at 9:00 am
mmHgTRAVATAN APSTRAVATAN
Mean Intraocular Pressure at 9:00 am17.9 ± 0.2518.1 ± 0.25
Statistical analysis
  • TRAVATAN APS vs TRAVATAN · Mean difference (final values): -0.2 · 95% CI -0.9 to 0.5Treatment group differences were calculated as the mean IOP in the Travoprost APS group minus the mean IOP in the Travatan group. Non-inferiority was demonstrated if the upper 95% CL of the between treatment difference in mean IOP was \< 1.5 mmHg.
PrimaryMean Intraocular Pressure at 11:00 am

For an individual patient, two consecutive IOP measurements for each eye were taken. The mean IOP values for each individual patient's eye were rounded up to the next whole number if the value was ≥ 0.5 mmHg All IOP measurements were performed with a Goldmann applanation tonometer. All IOP measurements for any individual subject were to be performed preferably by the same operator using the same tonometer. Mean IOP for the patient's worse eye at baseline was used in the primary endpoint analysis. If both eyes were equal, then the right eye was selected for analysis

Time frame:
3 months (measured at 11:00 am)
Reported as:
Least squares mean · mmHg
Mean Intraocular Pressure at 11:00 am
mmHgTRAVATAN APSTRAVATAN
Mean Intraocular Pressure at 11:00 am17.4 ± 0.2517.5 ± 0.25
Statistical analysis
  • TRAVATAN APS vs TRAVATAN · Median difference (final values): -0.1 · 95% CI -0.8 to 00.6Treatment group differences were calculated as the mean IOP in the Travoprost APS group minus the mean IOP in the Travatan group. Non-inferiority was demonstrated if the upper 95% CL of the between treatment difference in mean IOP was \< 1.5 mmHg.
PrimaryMean Intraocular Pressure at 4:00 pm

For an individual patient, two consecutive IOP measurements for each eye were taken. The mean IOP values for each individual patient's eye were rounded up to the next whole number if the value was ≥ 0.5 mmHg All IOP measurements were performed with a Goldmann applanation tonometer. All IOP measurements for any individual subject were to be performed preferably by the same operator using the same tonometer. Mean IOP for the patient's worse eye at baseline was used in the primary endpoint analysis. If both eyes were equal, then the right eye was selected for analysis

Time frame:
3 months (measured at 4:00 pm)
Reported as:
Least squares mean · mmHg
Mean Intraocular Pressure at 4:00 pm
mmHgTRAVATAN APSTRAVATAN
Mean Intraocular Pressure at 4:00 pm16.9 ± 0.2517.1 ± 0.25
Statistical analysis
  • TRAVATAN APS vs TRAVATAN · Median difference (final values): -0.2 · 95% CI -0.9 to 0.5Treatment group differences were calculated as the mean IOP in the Travoprost APS group minus the mean IOP in the Travatan group. Non-inferiority was demonstrated if the upper 95% CL of the between treatment difference in mean IOP was \< 1.5 mmHg.

Adverse events

Collected over 3 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TRAVATAN APS—1/185 (0.5%)32/185 (17.3%)
TRAVATAN—2/186 (1.1%)35/186 (18.8%)
Most frequent serious events
Most frequent serious events
EventTRAVATAN APSTRAVATAN
Abdominal massGastrointestinal disorders1/1850/186
Chest painGeneral disorders0/1851/186
PneumoniaInfections and infestations0/1851/186
Most frequent other events
Most frequent other events
EventTRAVATAN APSTRAVATAN
Ocular hyperaemiaEye disorders21/18519/186
Eye irritationEye disorders7/18511/186
Conjunctival hyperaemiaEye disorders8/18510/186

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TRAVATAN APSTRAVATANTotal
<=18 years000
Between 18 and 65 years94109203
>=65 years9177168
Sex: Female, Male
Sex: Female, Male(Participants)TRAVATAN APSTRAVATANTotal
Female112115227
Male7371144
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2009
First posted
Feb 20, 2009
Start
Mar 2009
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Results first posted
Mar 8, 2011
Last update
Apr 6, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00848536
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Feb 20, 2009
Start date
Mar 2009
Primary completion
Jan 2010
Completion
Jan 2010
Results posted
Mar 8, 2011
Last update
Apr 6, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion